Do you recommend hydroxyurea in patients with sickle cell disease with hereditary persistence of fetal hemoglobin who have recurrent vaso-occlusive crises requiring hospital admission?  

If hydroxyurea modifies the course of sickle cell disease by increasing fetal hemoglobin, is there any benefit to using it in patients with fetal hemoglobin over 20% if they continue to have several pain crises? Are there other mechanisms that contribute to disease modification? Would you consider voxelotor in these situations?

Answer from: at Academic Institution
Medical Oncologist at Clinical Instructor
I have a nearly identical patient with this scenar...
at University of Florida Health
Peds heme onc fellow here. Wondering what to consi...
at Boston University School of Medicine
Nearly all very young children respond to correct ...
Sign in or Register to read more